期刊文献+

抗p21 ras单克隆抗体与胃腺癌及正常胃粘膜组织的免疫反应性研究 被引量:3

Immunoreactivity of anti-p21 ras monoclonal antibody in gastric adenocarcinoma tissues and normal gastric tissues
下载PDF
导出
摘要 目的评价KGH-R1、KGH-R2、KGH-R3单克隆抗体(mAb)与胃腺癌组织及正常胃粘膜组织的免疫反应性,为临床应用奠定基础。方法用本实验室制备的三株广谱抗p21 ras mAb KGH-R1、KGH-R2、KGH-R3分别对30例正常胃粘膜组织、30例胃腺癌组织进行免疫组化染色,计算各样本的阳性细胞百分率和组织学评分(HSCORE),比较各组免疫反应性的差异。结果 (1)mAb KGH-R1与83.33%(25/30)的胃腺癌发生免疫反应,阳性样本的阳性细胞百分率为61.26%,HSCORE评分94.52分;与33.33%(10/30)的正常胃粘膜上皮发生免疫反应,阳性样本的阳性细胞百分率为10.00%,HSCORE评分为10.00分。(2)KGH-R2与86.67%(26/30)的胃腺癌发生免疫反应,阳性样本的阳性细胞百分率为86.04%,HSCORE评分155.29分;与23.33%(7/30)的正常胃粘膜上皮发生免疫反应,阳性样本的阳性细胞百分率为7.86%,HSCORE评分为7.86分。(3)KGH-R3与70.00%(21/30)的胃腺癌发生免疫反应,阳性样本的阳性细胞百分率为54.74%,HSCORE评分82.26分;与33.33%(10/30)的正常胃粘膜上皮发生免疫反应,阳性样本的阳性细胞百分率为9.15%,HSCORE评分为9.15分。(4)mAb KGH-R2 HSCORE分值与胃腺癌的浸润深度有关(P<0.05),与组织分化和淋巴结转移无关。结论抗p21 rasmAb KGH-R1、KGH-R2、KGH-R3与胃腺癌具有较好的免疫反应性,只与部分正常胃粘膜呈微弱阳性反应,可开发为治疗性抗体。 Objective To investigate the immunoreactivity of anti-p21ras monoclonal antibody(mAb) KGH-R1,KGH-R2 and KGH-R3 in gastric adenocarcinoma tissues and normal gastric tissues.Methods Immunohistochemical staining was performed in 30 samples from normal gastric tissues and 30 samples from gastric carcinoma tissues using above three monoclonal antibodies prepared in our laboratory.The immunoreactivity of monoclonal antibody KGH-R1,KGH-R2 and KGH-R3 was evaluated by percentage of positive cells and histological score(HSCORE).Then the findings were compared between the two groups.Results(1)Positive immunostaining of mAb KGH-R1 was found in 83.33%(25/30) of gastric adenocarcinoma,and 61.26% of cancer cells was positive with 94.52 of HSCORE on average.33.33%(10/30) of normal gastric tissues showed positive immunostaining with KGH-R1,but the average percentage of positive cells was 10.00% and the average HSCORE was 10.00.(2) Positive immunostaining of mAb KGH-R2 was found in 86.67%(26/30) of gastric adenocarcinoma,and 86.04% of cancer cells was positive with 155.29 of HSCORE on average.23.33%(7/30) of normal gastric tissues showed positive immunostaining with KGH-R2,but the average percentage of positive cells was 7.86% and the average HSCORE was 7.86.(3) Positive immunostaining of mAb KGH-R3 was found in 70.00%(21/30) of gastric adenocarcinoma,and 54.74% of cancer cells was positive with 82.26 of HSCORE on average.33.33%(10/30) of normal gastric tissues showed positive immunostaining with KGH-R3,but the average percentage of positive cells was 9.15% and the average HSCORE was 9.15.(4) There was a significant correlation between mAb KGH-R2 HSCORE and tumor invasive degree(P0.05),although mAb KGH-R2 HSCORE had no significant correlations with lymphatic metastasis and histological differentiation.Conclusion mAb anti-p21ras KGH-R1,KGH-R2 and KGH-R3 have high immunoreactivity with gastric adenocarcinoma while only weak positive reaction with partial normal gastric mucosa.There
出处 《西南国防医药》 CAS 2011年第6期581-584,共4页 Medical Journal of National Defending Forces in Southwest China
基金 国家自然科学基金项目(30872994) 云南省科技攻关项目(2006SG11)
关键词 胃腺癌 P21 RAS MAB KGH-R1 MAB KGH-R2 MAB KGH-R3 免疫反应性 gastric adenocarcinoma p21ras KGH-R1 KGH-R2 KGH-R3 immunoreactivity
  • 相关文献

参考文献17

  • 1Chesa P G,Rettig W J,Melamed M R,et al.Expression of p21ras in normal and malignant human tissues:lack of association with proliferation and malignancy[J].Proc Natl Acad Sci USA,1987,84:3234. 被引量:1
  • 2Ross J S,Schenkein D P,Pietrusko R,et al.Targeted therapies for cancer 2004[J].Am J Clin Pathol,2004,122:598-609. 被引量:1
  • 3Young A,Lyons J,Miller A L,et al.Ras signaling and therapies[J].Adv Cancer Res,2009,102:1-3. 被引量:1
  • 4陈昊宾,刘杜先,王丽,陈玥,宋蜀伶,杨丽琳,郝岩,杨举伦.抗p21Ras单克隆抗体KGH-R1在大肠良恶性病变中的免疫反应性比较[J].细胞与分子免疫学杂志,2010,26(12):1206-1209. 被引量:5
  • 5杨丽英,甄时建,王丽,陈玥,宋蜀伶,杨丽琳,杨举伦.抗p21ras单克隆抗体KGH-R1在乳腺癌组织中的免疫反应性[J].临床与实验病理学杂志,2011,27(1):34-39. 被引量:9
  • 6虞积耀,崔金才,译.世界卫生组织肿瘤分类及诊断标准系列(消化系统肿瘤病理学和遗传学)[M].北京:人民卫生出版社,2006:52. 被引量:1
  • 7Huang C L,Yokomise H,Kobayashi S,et al.Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy[J].Int J Oncol,2000,17:47-54. 被引量:1
  • 8Huang C,Liu D,Masuya D,et al.Clinical application of biological markers for treatments of resectable non-small-cell lung cancers[J].Br J Cancer,2005,92:1231-1239. 被引量:1
  • 9Shariat S F,Tokunaga H,Zhou J,et al.p53,p21,pRB,and p16 expression predict clinical outcome in cystectomy with bladder cancer[J].J Clin Oncol,2004,22:1014-1024. 被引量:1
  • 10Aoyagi K,Kohfuji K,Yano S,et al.The expression of proliferating cell nuclear antigen,p53,p21,and apoptosis in primary gastric lymphoma[J].Surgery,2002,132:20-26. 被引量:1

二级参考文献31

  • 1DeFce-Joues D,Tatehell K,Robinson LC,et al.Mammlian and yeast ras gene products:biological function in their heterelogous systems[J].Science,1985,228(4696):179-184. 被引量:1
  • 2Ross JS,Schenkein DP,Pietrusko R,et al.Targeted therapies for cancer 2004[J].Am J Clin Pathol,2004,122(4):598-609. 被引量:1
  • 3Yoang A,Lyons J,Miller AL,et al.Res signaling and therapies[J].Adv Cancer Res,2009,102(1):1-17. 被引量:1
  • 4Huang CL,Yokomise H,Kobayoshi S,et al.Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrngenase in nonsmall cell lung cancer patients treated with 5-FU-bnsed chemotherapy[J].Int J Oncol,2000,17(1):47-54. 被引量:1
  • 5Huang C,Liu D,Masuya D,et al.Clinical application of biolngical markers for treatments of resectsble non-small-cell lung cancera[J].Br J Cancer,2005,92(7):1231-1239. 被引量:1
  • 6Shariat SF,Tokunaga H,Zhou J,et al.p53,p21,pRB,and p16 expression predict clinical outcome in cystectomy with bladder cancer[J].J Clin Oncol,2004,22(6):1014-1024. 被引量:1
  • 7Jansson DS,Radosevich JA,Carney WP,et al.An immunohistochemical analysis of ras oncngene expression in epithelial neoplasms of the colon[J].Cancer,1990,65(6):1329-1337. 被引量:1
  • 8Ieda S,Watatani M,Yoshida T,et al.Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas[J].Surg Today,1996,26(4):230-235. 被引量:1
  • 9Usadi R S,Groll J M,Lessey B A,et al.Endometrial development and function in experimentally induced luteal phase deficiency[J].J Clin Endocrinol Metab,2008,93:4058-64. 被引量:1
  • 10Pallares J,Llobet D,Santacana M,et al.CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation[J].Am J Pathol,2009,174:287-96. 被引量:1

共引文献22

同被引文献43

  • 1肖恩华,胡国栋.化疗栓塞对肝细胞癌癌基因ras/p21表达的影响[J].放射学实践,2004,19(7):474-476. 被引量:1
  • 2SJ Moghaddam,EN Haghighi,S Samiee,N Shahid,AR Keramati,S Dadgar,MR Zali.Immunohistochemical analysis of p53,cyclinD1,RB1,c-fos and N-ras gene expression in hepatocellular carcinoma in Iran[J].World Journal of Gastroenterology,2007,13(4):588-593. 被引量:73
  • 3Castellucci P,Perrone A M,Picchio M.Diagnostic accuracy of 18T-FDG PET/CT inchaacterizing ovrian lesions and staging ovarian cancer:correlation with transvaginal ultrasonography,computed tomography,and hitology[J].Nucl Med Commun,2009,28(8):589-595. 被引量:1
  • 4Downward J.Targeting Ras signalling pathways in cancer therapy[J].Nature Reviews Cancer,2003,3(1):11-22. 被引量:1
  • 5Huang C,Liu D,Masuya D.Clinical application of biological markers for treatments of resectable non-small-cell lung cancers[J].Br J Cancer,2005,92(7):1231-1239. 被引量:1
  • 6Huang C L,Yokomise H,Kobayashi S.Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy[J].Int J Oncol,2000,17(1):47-54. 被引量:1
  • 7Shariat S F,Tokunaga H,Zhou J.p53,p21,pRB,and p16 expression predict clinical outcome in cystectomy with bladder cancer[J].J Clin Oncol,2004,22(6):1014-1024. 被引量:1
  • 8Aoyagi K,Kohfuji K,Yano S.The expression of proliferating cell nuclear antigen,p53,p21,and apoptosis in primary gastric lymphoma[J].Surgery,2002,132(1):20-26. 被引量:1
  • 9Calvisi D F,Ladu S,Gorden A.Ubiquitous activation of Ras and Jak/Stat pathways in human HCC[J].Gastroenterology,2006,130(4):1117-1128. 被引量:1
  • 10Bose S,Sakhuja P,Bezawada L.Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling[J].J Gastroenterol Hepatol,2011,26(1):135-144. 被引量:1

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部